Ideaya Biosciences Has Initiated A Phase 1 Monotherapy Expansion In The First-in-human Clinical Trial Evaluating Ide161 In Patients Having Tumors With Homologous Recombination Deficiency; Clinical Program Updates Is Expected In 2H Of 2023
Portfolio Pulse from Benzinga Newsdesk
Ideaya Biosciences has initiated a Phase 1 monotherapy expansion in the first-in-human clinical trial evaluating IDE161 in patients with tumors having homologous recombination deficiency. Clinical program updates are expected in the second half of 2023.
September 11, 2023 | 10:05 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ideaya Biosciences has initiated a Phase 1 trial for IDE161, a potential new treatment for patients with tumors having homologous recombination deficiency. This could potentially impact the company's stock positively in the long term, but updates are not expected until the second half of 2023.
The initiation of a Phase 1 trial is a positive step for Ideaya Biosciences, indicating progress in their research and development efforts. However, as updates on the trial are not expected until the second half of 2023, the immediate impact on the company's stock is likely to be neutral. The long-term impact could be positive if the trial results are successful.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100